Bempikibart demonstrated robust clinical activity and a favorable safety profile in severe/very severe alopecia areata over 36 weeks, with durable responses and deepening effects observed off-drug. The results support advancement to registrational studies and highlight potential to address significant unmet need in the growing US market.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.